Amgen stock holds firm after a Q2 2026 earnings beat
Published on 08/29/2026 at 06:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen Inc. (US0311621009) stock is backed by a Q2 2026 earnings beat, with revenue of $10.05 billion and adjusted EPS of $6.29 for the quarter ended June 30, 2026. The latest session cited in market coverage showed shares opening at $436.99, while the stock also traded near a one-year high of $447.03.
In the same quarter, revenue rose 9.5% from a year earlier and EPS improved from $6.02, a clean quantified comparison that shows the core business still expanding. The company also lifted FY 2026 guidance to $22.30-$23.50 per share, while analysts in market coverage were looking for $22.92.
Guidance stays the focal point
The raised outlook matters because it puts the midpoint of management's range at $22.90, just above the consensus figure cited in market coverage. That leaves the next earnings update and franchise execution more important than any single daily move.
For investors, the key message is simple: Amgen's 9.5% revenue growth, $6.29 quarterly EPS and full-year EPS range of $22.30-$23.50 all point to a business that entered the second half with momentum. The dividend also adds to the picture, with a quarterly payout of $2.52 per share, equal to a 2.3% annualized yield.
Analysts remain constructive
Recent coverage also pointed to a fresh Buy call with a $452.00 target and a separate Buy reiteration with a $450.00 target. The consensus view cited in the same coverage showed a Moderate Buy rating and a $394.73 average target, which leaves room for disagreement even as sentiment stays positive.
That spread matters. It suggests the stock is no longer being judged only on one quarter's numbers, but on whether management can keep growth, margin and guidance aligned into the rest of 2026.
Repatha still matters
One of Amgen's best-known products is Repatha, the cholesterol-lowering treatment that remains a key part of the company's growth portfolio. The product mix matters because Amgen's Q2 2026 beat was not driven by a single line item; it came alongside broad portfolio performance and a higher full-year outlook.
Shares and valuation
Amgen stock opened at $436.99 in the latest cited session and traded well above the $363.86 200-day moving average referenced in market coverage. The combination of a $447.03 one-year high, $436.99 opening price and $10.05 billion in quarterly revenue gives the stock a valuation backdrop that still looks tied to execution.
Fact box
Company: Amgen Inc.
ISIN: US0311621009
Ticker: AMGN
Exchange: Nasdaq
Sector / Industry: Health Care / Biotechnology
Index membership: S&P 500
Price (as of August 27, 2026): $436.99 USD
Market cap: $234.4 billion (as of August 27, 2026)
Next earnings date: October 27, 2026
More on Amgen stock
Repatha is one of the clearest reminders that Amgen's portfolio still has multiple growth drivers beyond the headline quarter. That is what keeps the stock anchored to reported numbers rather than to a single catalyst.
Amgen stock closed the latest cited session at $436.99, with a one-year high of $447.03 and a 200-day moving average of $363.86. The market cap stood at $234.4 billion on August 27, 2026.
